Frequency Therapeutics is a clinical-stage biotech harnessing its Progenitor Cell Activation (PCA) platform to activate progenitor cells in situ and regenerate functional tissue. Its lead program, FX-322, is a potential first-in-class regenerative therapeutic targeting hearing restoration and is moving into a Phase 2a study for sensorineural hearing loss. The company plans to use proceeds from its recent financing to support FX-322’s clinical development and to advance discovery programs in other therapeutic areas including muscle, gastrointestinal, skin, and bone. Frequency recently announced a collaboration with Astellas that included an $80 million upfront payment and up to $545 million in potential milestone payments to support global development and ex‑US commercialization of FX-322. The company emphasizes reducing regenerative‑medicine complexity by leveraging innate biology with small molecules rather than cell or gene therapies. Frequency is based in Woburn, Massachusetts and is positioning its PCA platform as a source of new treatments across multiple degenerative-disease indications. Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Mass., developing a new class of small-molecule drugs that stimulate dormant progenitor cells (Progenitor Cell Activation, PCA) to repair diseased or damaged tissue. Its lead candidate, FX-322, targets sensorineural hearing loss and is being advanced for hearing regeneration. The company planned to move FX-322 into Phase 2 studies in 2019 and expected top-line Phase 1/2 results in the first half of 2019. Frequency highlights that its PCA approach enables native tissue regeneration without genetic modification or removal of cells, avoiding risks of genetic engineering and manufacturing challenges of cell therapy. Proceeds from the financing will support advancement of FX-322 and continued expansion of the PCA Regeneration pipeline into new therapeutic applications. Frequency has raised a total of $87 million to date. Frequency Therapeutics develops small‑molecule drugs that transiently activate progenitor cells using its proprietary Progenitor Cell Activation (PCA™) platform; its lead program targets chronic noise‑induced hearing loss by stimulating regrowth of inner ear sensory hair cells. The company holds a worldwide exclusive license to related intellectual property from MIT and Partners Healthcare and cites foundational work by co‑founders Robert Langer and Jeffrey Karp. Frequency was founded in 2015 and lists David Lucchino as co‑founder, president and CEO. It plans to move its lead program into the clinic in the next 12–18 months and is positioning PCA for additional indications including skin disorders, muscle regeneration and gastrointestinal diseases. Financially, Frequency closed a $32 million Series A to support clinical development, with participation from U.S. and international investors.

Total raised

$136M

Funding rounds

3

Latest round

Series C

Latest activity

Jul 2019